Key terms
About CERS
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CERS news
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 20
8:15pm ET
Cathie Wood’s ARK Investment bought 193K shares of Cerus today
Mar 19
8:08am ET
Cerus announces ReCePI trial met primary efficacy endpoint
Mar 18
8:17pm ET
Cathie Wood’s ARK Investment bought 278K shares of Cerus today
Mar 18
6:27am ET
Cerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ Rating
Mar 13
8:06pm ET
Cathie Wood’s ARK Investment bought 296K shares of Cerus today
Mar 13
6:10am ET
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Mar 07
1:00am ET
Cerus Corporation’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Mar 06
7:37am ET
Stifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)
Mar 05
4:29pm ET
Cerus affirms 2024 product revenue guidance
Mar 05
4:03pm ET
Cerus reports Q4 EPS (1c) , consensus (2c)
Jan 07
5:30am ET
Cerus (CERS) Receives a Hold from BTIG
Jan 02
9:14am ET
Cerus (CERS) Receives a Hold from BTIG
Dec 31
5:09am ET
BTIG Remains a Hold on Cerus (CERS)
No recent news articles are available for CERS
No recent press releases are available for CERS
CERS Financials
Key terms
Ad Feedback
CERS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CERS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range